X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
BMS-984923 (ALX-001) is a highly selective, first-in-class, synapse-targeted, disease-modifying oral therapy, which is being evaluated for the treatment of Alzheimer’s and Parkinson’s disease.
Lead Product(s): ALX-001
Therapeutic Area: Neurology Product Name: BMS-984923
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2024
Details:
ALX-001 is a highly selective, first-in-class, synapse-targeted, disease-modifying oral therapy for neurodegenerative diseases. It is being evaluated for the treatment of Parkinson’s Disease.
Lead Product(s): ALX-001
Therapeutic Area: Neurology Product Name: ALX-001
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2024
Details:
ALX-001 (previously BMS-984923) is a oral silent allosteric modulator of mGluR5, and the first-in-class compound that selectively blocks the pathogenic activation of the receptor while preserving normal glutamate signaling, being investigated for neurodegenerative diseases.
Lead Product(s): BMS-984923
Therapeutic Area: Neurology Product Name: ALX-001
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 30, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
